Modulating Endothelialization of Cardiovascular Grafts

调节心血管移植物的内皮化

基本信息

  • 批准号:
    6969959
  • 负责人:
  • 金额:
    $ 32.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-07-01 至 2009-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): A durable bioprosthetic vascular graft is badly needed for vascular bypass surgery. For peripheral vascular surgery, there is essentially no viable alternative to an autogenous venous conduit to bypass leg arteries. In part, the challenges to establishing an endothelialized graft have been gaps in our understanding of how specific growth factors and matrix proteins interact with each other and modulate cellular responses. Heparins are known to modulate growth responses, but heparin's effects have been confusing and contradictory, due to the heterogeneity of heparin's structure and its diverse interactions. We have discovered that vascular endothelial growth factor (VEGF) and fibronectin (Fn) have a unique and dedicated biologic partnership. Fn binds VEGF like no other matrix protein, and Fn significantly enhances the endothelial migration and proliferation mediated by VEGF. Their cognate receptors, alpha5beta1 and VEGFR2 also work in synergy. We have also demonstrated that VEGF-Fn complexes uniquely enhance the differentiation of endothelial progenitor cells (EPC) into the endothelial line. Our goals are: 1) Elucidate the mechanisms underlying Fn promotion of VEGF activity, 2) Define the structure-activity relations of heparin's modulation of VEGF-VEGFR2 binding, 3) Define and develop recombinant fibronectin constructs and heparin oligosaccharides that when combined with VEGF and EPC will enhance endothelialization of a porous vascular graft, by capillary in growth and the differentiation of EPC. Using recombinant Fn constructs, we will identify the Fn domains that are key to promoting VEGF mitogenic effects. Using structurally defined synthetic oligosaccharides, and novel surface plasmon resonance technology we will identify the optimal size and structure of heparin that promotes VEGF binding to its receptor VEGFR2. In an animal model of peripheral artery bypass grafting that closely resembles the human condition, we will test these constructs and cells for their ability to promote the growth of a stable endothelial lining.
描述(由申请人提供):血管搭桥手术急需耐用的生物假体血管移植物。对于外周血管手术,基本上没有可行的替代自体静脉导管来绕过腿部动脉。在某种程度上,建立内皮化移植物的挑战在于我们对特定生长因子和基质蛋白如何相互作用并调节细胞反应的理解存在差距。众所周知,肝素可以调节生长反应,但由于肝素结构的异质性及其相互作用的多样性,肝素的作用一直令人困惑和矛盾。我们已经发现血管内皮生长因子(VEGF)和纤维连接蛋白(Fn)有一个独特的和专用的生物伙伴关系。Fn不像其他基质蛋白那样与VEGF结合,Fn显著增强VEGF介导的内皮细胞迁移和增殖。它们的同源受体,alpha5beta1和VEGFR2也协同工作。我们也证明了VEGF-Fn复合物能够独特地促进内皮祖细胞(EPC)向内皮细胞系的分化。我们的目标是:1)阐明Fn促进VEGF活性的机制;2)确定肝素调节VEGF- vegfr2结合的构效关系;3)确定并开发重组纤维连接蛋白构建物和肝素低聚糖,当它们与VEGF和EPC结合时,将通过毛细血管生长和EPC分化增强多孔血管移植物的内皮化。利用重组Fn结构体,我们将确定促进VEGF有丝分裂作用的Fn结构域。利用结构明确的合成寡糖和新型表面等离子体共振技术,我们将确定促进VEGF与其受体VEGFR2结合的肝素的最佳大小和结构。在一个与人类情况非常相似的外周动脉搭桥移植动物模型中,我们将测试这些构建物和细胞促进稳定内皮细胞生长的能力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL SOBEL其他文献

MICHAEL SOBEL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL SOBEL', 18)}}的其他基金

Acquisition of Shared Equipment - Cell Analyzer/Flow Cytometer
购置共享设备 - 细胞分析仪/流式细胞仪
  • 批准号:
    8949386
  • 财政年份:
    2015
  • 资助金额:
    $ 32.47万
  • 项目类别:
Preventing Vein Graft Stenosis in Peripheral Vascular Surgery
预防外周血管手术中移植静脉狭窄
  • 批准号:
    8455698
  • 财政年份:
    2012
  • 资助金额:
    $ 32.47万
  • 项目类别:
Preventing Vein Graft Stenosis in Peripheral Vascular Surgery
预防外周血管手术中移植静脉狭窄
  • 批准号:
    8331692
  • 财政年份:
    2012
  • 资助金额:
    $ 32.47万
  • 项目类别:
Preventing Vein Graft Stenosis in Peripheral Vascular Surgery
预防外周血管手术中移植静脉狭窄
  • 批准号:
    8698397
  • 财政年份:
    2012
  • 资助金额:
    $ 32.47万
  • 项目类别:
Modulating Endothelialization of Cardiovascular Grafts
调节心血管移植物的内皮化
  • 批准号:
    7081322
  • 财政年份:
    2005
  • 资助金额:
    $ 32.47万
  • 项目类别:
Modulating Endothelialization of Cardiovascular Grafts
调节心血管移植物的内皮化
  • 批准号:
    7469475
  • 财政年份:
    2005
  • 资助金额:
    $ 32.47万
  • 项目类别:
Modulating Endothelialization of Cardiovascular Grafts
调节心血管移植物的内皮化
  • 批准号:
    7270643
  • 财政年份:
    2005
  • 资助金额:
    $ 32.47万
  • 项目类别:
PLATELET-HEPARIN INTERACTIONS IN CARDIOVASCULAR SURGERY
心血管手术中的血小板-肝素相互作用
  • 批准号:
    3471854
  • 财政年份:
    1988
  • 资助金额:
    $ 32.47万
  • 项目类别:
PLATELET-HEPARIN INTERACTIONS IN CARDIOVASCULAR SURGERY
心血管手术中的血小板-肝素相互作用
  • 批准号:
    2219429
  • 财政年份:
    1988
  • 资助金额:
    $ 32.47万
  • 项目类别:
PLATELET-HEPARIN INTERACTIONS IN CARDIOVASCULAR SURGERY
心血管手术中的血小板-肝素相互作用
  • 批准号:
    3356871
  • 财政年份:
    1988
  • 资助金额:
    $ 32.47万
  • 项目类别:

相似海外基金

Pioneering reproductive biotechnology innovations for equine breeding
开创马匹育种生殖生物技术创新
  • 批准号:
    LP230100156
  • 财政年份:
    2024
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Linkage Projects
Industrial Biotechnology Innovation Cluster
产业生物技术创新集群
  • 批准号:
    EP/Y024168/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Research Grant
Environmental Biotechnology Innovation Centre
环境生物技术创新中心
  • 批准号:
    BB/Y008332/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Research Grant
Shear Innovation: Valorising wool waste using biotechnology to enhance horticultural peat-free growing media
剪切创新:利用生物技术提高羊毛废料的价值,以增强园艺无泥炭生长介质
  • 批准号:
    10106787
  • 财政年份:
    2024
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Launchpad
Conference: Translating Molecular Science Innovations into Biotechnology Solutions
会议:将分子科学创新转化为生物技术解决方案
  • 批准号:
    2419731
  • 财政年份:
    2024
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Standard Grant
MFB: Partnerships to Transform Emerging Industries - RNA Tools/Biotechnology: Stabilizing Hairpin Inserts in RNA Virus Induced Gene Silencing Vectors
MFB:合作变革新兴产业 - RNA 工具/生物技术:稳定 RNA 病毒诱导基因沉默载体中的发夹插入
  • 批准号:
    2330663
  • 财政年份:
    2024
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Standard Grant
I-Corps: Translation potential of a miniaturized biotechnology platform for nucleic acid extraction, purification, and library preparation
I-Corps:用于核酸提取、纯化和文库制备的小型生物技术平台的转化潜力
  • 批准号:
    2421022
  • 财政年份:
    2024
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Standard Grant
NSF Convergence Accelerator Track M: Biofilm-based Corrosion Control using 3D Printed Biotechnology
NSF 融合加速器轨道 M:使用 3D 打印生物技术进行基于生物膜的腐蚀控制
  • 批准号:
    2344389
  • 财政年份:
    2024
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Standard Grant
Engineering Biology Hub for environmental processing and recovery of metals; from contaminated land to industrial biotechnology in a circular economy
用于环境处理和金属回收的工程生物中心;
  • 批准号:
    BB/Y008456/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Research Grant
Conference: 2023 Chloroplast Biotechnology GRC & GRS: Harnessing the SynBio Revolution for Metabolic Engineering and Enhanced Photosynthesis
会议:2023年叶绿体生物技术GRC
  • 批准号:
    2243932
  • 财政年份:
    2023
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了